Canada: Patent

The Supreme Court of Canada has issued its most significant ruling on medical treatment patents in over fifty years, addressing whether dosing-regimen claims for schizophrenia medication constitute unpatentable methods of medical treatment. The 7-2 decision establishes a new framework for evaluating pharmaceutical patents, focusing on whether implementing the claimed invention requires professional medical skill and judgment. This landmark case provides crucial guidance for life sciences companies seeking p

La Cour suprême du Canada a rendu une décision historique confirmant que les méthodes de traitement médical demeurent non brevetables lorsqu'elles monopolisent la compétence et le jugement professionnels des médecins.

Section 7(a) of the Trademarks Act precludes anyone from making a false or misleading statement tending to discredit the business, goods or services of a competitor.

The Supreme Court of Canada has ruled on the patentability of methods of medical treatment in Canada, affirming that such methods remain unpatentable while upholding the validity of Janssen's patent for a paliperidone palmitate dosing regimen. The decision provides crucial guidance on determining whether pharmaceutical claims constitute unpatentable medical treatment methods, focusing on the role of professional medical skill and judgment in practicing the claimed invention.

The Supreme Court of Canada has issued a landmark ruling on whether methods of medical treatment can be patented in Canada, addressing a long-standing prohibition that has shaped the country's intellectual property landscape. The decision examines the boundaries between patentable medical innovations and unpatentable professional medical judgment, with particular focus on dosing regimens and treatment protocols. This ruling provides critical guidance for pharmaceutical companies, patent practitioners, and h

L'équipe responsable des mises à jour PI Rx examine les développements majeurs en propriété intellectuelle et en droit réglementaire des sciences de la vie au Canada durant le premier semestre 2026, incluant les nouvelles lignes directrices de la Cour fédérale, les initiatives de Santé Canada et les mises à jour du CEPMB et de l'AMC.

Saskatchewan startups often discover too late that unclear intellectual property ownership can derail fundraising and acquisitions. When founders, contractors, or employees contribute to a company's IP without proper documentation...

AccelerateIP offers Canadian startups substantial funding and mentorship to develop intellectual property strategies, with three program streams providing up to $85,000 in combined support for IP development, legal costs...

In today’s competitive marketplace, intellectual property (IP) and the IP rights that protect them are often among the most valuable assets a company possesses.